View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsNeonMind Biosciences 将来の成長Future 基準チェック /06現在、 NeonMind Biosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 15Lancaster Lithium Inc. signed a binding letter agreement to acquire NeonMind Biosciences Inc. (CNSX:NEON) for CAD 0.19 million in a reverse merger transaction.Lancaster Lithium Inc. signed a binding letter agreement to acquire NeonMind Biosciences Inc. (CNSX:NEON) for CAD 0.19 million in a reverse merger transaction on December 14, 2022. At the closing of the Transaction, NeonMind will acquire 100% of the outstanding securities in Lancaster Lithium in exchange for the issuance of post-Consolidation NeonMind shares on a 1:1 basis. Prior to the closing of the Transaction, NeonMind is obligated to complete the consolidation of shares at the ratio of one new share for every thirty existing shares. The completion of the Transaction is subject to the satisfaction of various conditions that are customary for a transaction of this nature, including but not limited to; the completion of the Consolidation; NeonMind and Lancaster Lithium obtaining all required director and shareholder approvals; and the receipt of all requisite regulatory, stock exchange or governmental authorizations and consents, including the authorization and consent of the CSE. Closing of the Transaction to occur no later than March 4, 2022.お知らせ • Dec 10+ 1 more updateNeonMind Biosciences Inc. Announces CEO ChangesNeonMind Biosciences Inc. announced that Rob Tessarolo, a director on the NeonMind Board of Directors, was appointed Chief Executive Officer on December 7, 2022. Mr. Tessarolo replaces Penny White, who has resigned as Chief Executive Officer as of December 7, 2022, but continues to serve as a director of the Company. Rob joined the Company in January 2021 and is an experienced executive who brings over 25 years of experience in management. The CEO and Board of Directors are currently reviewing new opportunities and are seeking a buyer for the Company's drug development program.Board Change • Nov 16No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Co-Founder, CEO & Director Penny White is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • May 31+ 1 more updateNeonMind Biosciences Inc. Announces Executive ChangesNeonMind Biosciences Inc. announced that has made changes to its Management, Board of Directors, and Advisory Board to support the Company's strategic plans. Effective May 30, 2022, Rob Tessarolo has been appointed as Chairman of the Board of NeonMind and has resigned from his role as President. Ms. White continues as a member of the Board of Directors. Also on May 30, 2022, Kari Richardson and Jeff B Smith resigned as Directors of the Board of Directors. Kari Richardson has been appointed to serve on the Company's advisory board. Cole Drezdoff and Rob Tessarolo have been appointed to the Company's Board of Directors to fill the vacancies. The Company's Board of Directors now consists of Rob Tessarolo, Penny White, and Cole Drezdoff, and each of them is a member of the Audit Committee, with Rob Tessarolo appointed as Audit Committee Chair. Ms. White continues as a member of the Board of Directors. Robert Tessarolo has 26 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of NeonMind from January 2021 to May 2022. Prior to that, he acted as President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., a psychedelic drug discovery and drug development company now traded on the NEO exchange, from September 2019 to January 2020. Prior, Mr. Tessarolo was President and Chief Executive Officer of Cipher Pharmaceuticals Inc., a diversified specialty pharmaceutical company listed on the Toronto Stock Exchange. Mr. Tessarolo has extensive strategic experience and an impressive operational record of scaling high growth organizations in the pharmaceutical industry through product innovation and M&A. Cipher Pharmaceuticals Inc., which focuses on acquisitions, inlicensing, and selective investments in drug development, under his leadership, was restored to positive EBITDA with the execution of seven business development transactions in less than 18 months. He was the first employee of Watson Pharmaceuticals in Canada. Under his leadership revenue grew from zero to $190 million and he led the Canadian integration of major M&A transactions including Watson integration of Warner Chilcott (~$5 billion global acquisition), Forest Laboratories (~$28 billion global acquisition) and Allergan (~$66 billion global acquisition) in less than 18 months. He has secured tens of millions in financing and hundreds of millions in revenue for companies under his leadership. Cole Drezdoff has been a Director and member of the Audit Committee of Better Plant Sciences Inc. since July 2020. He recently completed four years of fulltime accounting and marketing courses at Toronto Metropolitan University at the Ted Rogers School of Management. Mr. Drezdoff developed experience over the past five years as a consultant in social media, sales, investor relations and business development.Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Executive Chairperson Penny White is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 20NeonMind Biosciences Inc Engages Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health ClinicNeonMind Biosciences Inc. announced it has advanced its strategy to enhance access to treatments at its specialty mental health clinics with Impetus Digital in preparation of opening its inaugural clinic located in Mississauga, Ontario. Intravenous ketamine for mood and anxiety disorders (IV-Ket) was recently included in the Canadian guidelines as a recommended treatment. As a testament to the value of IV-Ket treatments, a growing number of prescribers and their patients are seeking access to this treatment with further opportunities to expand the prescriber base through medical education. NeonMind will be working with Impetus Digital's InSite Platform®, a trusted platform for virtual medical education to enhance adoption of IV-Ket treatments. This platform will enable to establish prescriber confidence to include IV-Ket in their treatment toolset and how to refer patients to NeonMind clinics. Impetus Digital has been integral in successful pharmaceutical and healthcare treatment launches in Canada.お知らせ • Apr 09NeonMind Biosciences Inc. announced that it has received CAD 0.285 million in fundingOn April 8, 2022, NeonMind Biosciences Inc. closed the transaction. The company has received gross proceeds of CAD 285,000 in the transaction. The company also issued 3,743,000 warrants to purchase common shares of the company. The company has paid CAD 14,000 cash commission and granted 133,000 warrants to Echelon Wealth Partners Inc.お知らせ • Feb 24NeonMind Biosciences Inc. Appoints Dinesh Bhayana as Site Medical Director of Its Inaugural Specialty Mental Health ClinicNeonMind Biosciences Inc. announced the appointment of Dr. Dinesh Bhayana, MD, CCFP (EM), as the Site Medical Director of its recently announced inaugural specialty clinic for interventional psychiatry, located in Mississauga, Ontario. Dr. Bhayana is the Chief Medical Officer of the Centre for Compassionate Care (C3), which offers specialized psychological services including Integrative Ketamine-Enhanced Psychotherapy, served as a Board Member for the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada, and an Emergency and Addiction Medicine physician in several communities within the Greater Toronto Area. NeonMind and Dr. Bhayana will work closely with medical leaders in NeonMind's Specialty Clinics Advisory Board to set up the Company's inaugural NeonMind specialty mental health clinic in Mississauga and leverage their clinical experience to meet regulatory licensing requirements and initiate treatment services this year.お知らせ • Feb 18NeonMind Biosciences Inc. Announces the Resignation of Amber Allen as Vice President of SalesNeonMind Biosciences Inc. announced the resignation of Amber Allen as Vice President of Sales effective January 17, 2022, which was in connection with the divestiture of the NeonMind consumer division assets.お知らせ • Nov 24NeonMind Biosciences Inc. Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001NeonMind Biosciences Inc. announced it successfully completed a pre-Investigational New Drug (IND) consultation with the U.S. Food and Drug Administration (FDA), regarding proposed clinical trials for NeonMind's lead obesity drug candidate, NEO-001. The Company expects to initiate a Phase 1/2 clinical study in the first half of 2022. The pre-IND consultation offered feedback for NeonMind to execute on measurable clinical development milestones for its NEO-001 clinical program. The FDA acknowledged the study rationale and potential therapeutic opportunity of NEO-001 for the treatment of obesity, and the justification to advance into human clinical trials. NeonMind will incorporate the FDA's recommendations and does not expect any impact on the timing of the proposed NEO-001 clinical program. NeonMind's proprietary therapy will be the first psychedelic program in humans to target a large population of patients struggling with sustainable weight management. NEO-001, the Company' lead drug candidate targeting obesity, is a high-dose psilocybin treatment coupled with behavioral therapy and lifestyle intervention, which aims to improve the efficacy of chronic weight management in adults. The Company has identified a regulatory strategy, including a target indication and product profile, which it believes will best position NeonMind as it advances its first lead candidate through development.お知らせ • Sep 14+ 1 more updateBetter Plant Sciences Inc. (CNSX:PLNT) acquired Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON).Better Plant Sciences Inc. (CNSX:PLNT) acquired Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON) on September 10, 2021. The consideration paid by Better Plant to NeonMind Biosciences CAD 0.645 million plus a royalty of 3% of net product sales payable by Better Plant to NeonMind Biosciences for 25 years, payable on cumulative net product sales of over CAD 1 million and payment of CAD 0.645 was made by setting off the balance due of CAD 0.645 on a note owed by NeonMind Biosciences to Better Plant which would have been payable in February 2022. Better Plant Sciences Inc. (CNSX:PLNT) completed the acquisition of Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON) on September 10, 2021.お知らせ • Jul 01Neonmind Biosciences Inc. Launches Its Neonmind Branded Functional Mushroom Coffee Products as Dietary Supplements in the United StatesNeonMind Biosciences Inc. announce that it is launched its NeonMind branded functional mushroom coffee products as dietary supplements in the United States. The initial launch includes two ground coffee SKUs that are available for delivery anywhere within the US. Two instant coffee SKUs are anticipated to be added within a month. Products can be purchased individually and can be ordered as a subscription to receive a 10% discount The website was built to be mobile friendly and focus on a customer- first strategy. Consumers can sign up to NeonMind's newsletter to receive the latest news, product releases and recipe information. Each of the functional mushroom blends and botanicals selected in NeonMind coffees include adaptogens, which means that they work with one's body to help manage physical, mental and emotional stressors. Functional mushroom specifically refers to mushroom varieties that have a health benefit beyond providing nutrition. Functional mushrooms found in NeonMind coffees, such as cordyceps, lion's mane, reishi, and turkey tail; offer long-term physical, neurological and immunological benefits. The initial product launch will feature two varieties of ground coffee. The Protect Blend is a Peruvian Medium Roast French Vanilla Coffee, Turkey Tail, Cordyceps, Moringa extract, and Amla extract. These ingredients have the proven benefit of stress relief, immune support, and cognitive support. The Focus Blend is a Peruvian Dark Roast Coffee with Lion's Mane extract, Reishi extract, Gotu Kola extract, and Brahmi extract. These ingredients are a healthy source of fungal polysaccharides with immuno- modulating properties that help improve memory and cognitive function, increase alertness, support the immune system and fight mental and physical stress. The Company will soon launch its two instant coffee blends in the US as dietary supplements. The NeonMind coffee dietary supplements follow all FDA regulations that focus on Comprehensive GMP (Good Manufacturing Practices) to ensure the identity, purity, quality, strength and composition of dietary supplements. NeonMind only uses certified organic mushroom extracts which go through the decoction process (traditional water boiling) to maximize the bioavailability of the product. NeonMindfollows strict US pharmacopeia guidelines for lead and other chemicals required by Proposition 65 for safe and daily intake. All final production batches are sent to a third party lab for stringent microbial testing in order for the copacker to release the product certificate of analysis which signifies that the product is safe for the consumer market.お知らせ • Mar 20NeonMind Biosciences Inc., Annual General Meeting, May 27, 2021NeonMind Biosciences Inc., Annual General Meeting, May 27, 2021. Location: Suite 800, 365 Bay Street Toronto Ontario Canadaお知らせ • Mar 04NeonMind Biosciences Inc. Files Four Additional Provisional Patents on Psilocybin Preclinical DataNeonMind Biosciences Inc. announced that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind's preclinical trial. The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind's proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time. This patent has also been included to support NeonMind's first filed U.S. provisional patent which has a priority date of December 4, 2019, and has been converted to a Patent Cooperation Treaty ("PCT") application. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in 152 countries. NeonMind's patent portfolio has potential rights in 152 countries including the United States. It has filed 10 US provisional patent applications, of which 2 have been converted to PCT applications. The anticipated patent protection expiry of these pending patents is 2041. NeonMind anticipates that its near term activities will support additional applications filed later this year. Compounds now covered by NeonMind's pending patents include: Psilocin, Psilocybin, 4-SH-dimethyltryptamine, 1-methylpsilocin, 4-fluoro-N,N-dimethyltryptamine, O-acetylpsilocin, 4-hydroxy-N-methyl-N-isopropyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, LSD, LSA, DMT. Treatments that are covered by NeonMind's pending patents include: Aiding Weight Loss, Obesity, Compulsive Eating Disorder, Diet Alteration, Reduction of Food Cravings, Decreasing Food Intake, Complications Associated with Obesity. NeonMind owns 100% of all of Its intellectual property except for patents surrounding LSD, LSA and DMT, of which it owns 80%. Translational Life Sciences Inc. a research collaborator, owns the remaining 20%.お知らせ • Feb 26NeonMind Biosciences Inc. Purchases GMP Grade Synthetic Psilocybin from Psygen Labs Inc. for Phase 2 Human Clinical TrialNeonMind Biosciences Inc. announced that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. for its planned phase 2 human clinical trial expected to begin in Canada later this year. The purchase is made pursuant to a restricted substance supply agreement between Psygen and NeonMind entered into on September 28, 2020. Last year NeonMind received supply under the agreement of non-GMP synthetic psilocybin for its preclinical trial which commenced last November. Now, with promising initial results from its preclinical trial, NeonMind has purchased the GMP grade synthetic psilocybin so it can move forward with an application to Health Canada for a phase 2 human clinical trial. The GMP grade synthetic psilocybin was manufactured through Psygen's collaboration with Applied Pharmaceutical Innovation ("API") and a licensed dealer at the University of Alberta. All the future material will be manufactured at Psygen's soon-to-be completed commercial facility in Calgary. NeonMind may not accept delivery of the psilocybin until it has received authorization from Health Canada. NeonMind filed a provisional patent application in the US, later converted to a patent application, for therapeutic administration of psilocybin alone or in combination with psychotherapy. The patent focuses on psilocybin's potential health benefits for aiding weight loss, diet alterations, reducing food cravings, decreasing food intake, and related health complications. NeonMind plans to study the use of psilocybin alone and in combination with psychotherapy as a treatment for obesity.お知らせ • Feb 11NeonMind Biosciences Inc. Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight StressNeonMind Biosciences Inc. ("NeonMind"), announced that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD), to obtain product licenses for its products with 100% plant-based extracts, and make their related health claims. The formulas primarily consist of combinations of medicinal mushrooms: Lion's Mane, Reishi, Turkey Tail and Cordyceps. Certain herbs traditionally used in Ayurveda were also included in the formulas. The NeonMind proprietary formulas were created by an expert of Ayurvedic medicine. If the claim applications are deemed acceptable through Health Canada's regulatory review process, then NeonMind will be able to launch natural health products in Canada containing the herbal and fungi formulations described in the NHP applications. Under the natural health product number ("NPN") assigned by Health Canada, NeonMind will be allowed to market these products in different capacities as long as they contain the same makeup and quantities of herbs that are authorized for sale by Health Canada. Health claims submitted as part of the NHP applications by NeonMind include claims that one or more of the formulas can help support memory and cognitive function, support the body's immune response, be used as an adaptogen to help increase energy and resistance to stress (in the case of mental and physical fatigue related to stress), relieve pain and inflammation, and the claim of traditional use in Ayurveda to relieve general debility (especially during convalescence or old age). All natural health products need to obtain a product licence with detailed information about the medicinal ingredients, source, dose, potency, non medicinal ingredients, recommended use, and appropriate risk mitigation statements to be sold in Canada. Once the product is assessed to be safe, effective and of high quality Health Canada issues a product licence an NPN number, allowing it to make health claims. eonMind's consumer products division currently has four mushroom infused coffees that do not contain any psychoactive or restricted substances for sale in Canada through NeonMind's direct-to-consumer ecommerce platform at neonmind.com. NeonMind has plans to launch additional products in Canada as natural health products if Health Canada approves its recent applications. NeonMind's consumer division operates in the rapidly growing functional food market. NeonMind also plans to launch dietary supplements in the United States and is currently developing products and packaging for four products to be manufactured to comply with the United States Food and Drug Administration (FDA) rules. NeonMind plans to roll out these products for sale in the U.S. in spring 2021. In addition to its consumer products division, NeonMind's pharmaceutical division is engaged in the research and development of drugs and treatments for obesity and obesity related diseases using psychedelic compounds. It is currently engaged in a preclinical trial examining its patent pending treatment of obesity through the administration of psilocybin and is currently developing protocols for a phase 2 human clinical trial.Recent Insider Transactions • Feb 03Co-Founder & Executive Chairperson recently bought CA$76k worth of stockOn the 29th of January, Penny White bought around 282k shares on-market at roughly CA$0.27 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$425k. This was Penny's only on-market trade for the last 12 months.お知らせ • Jan 29Neonmind Biosciences Inc. Announces CEO ChangesNeonMind Biosciences Inc. announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as its Chief Executive Officer. Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., from September 2019 to January 2020. Prior, Mr. Tessarolo was President and Chief Executive Officer of Cipher Pharmaceuticals Inc. In preparation for Robert Tessarolo's appointment, NeonMind founder Penny White steps down as President and CEO of NeonMind.お知らせ • Jan 28NeonMind Biosciences Inc. Appoints Robert Tessarolo as PresidentNeonMind Biosciences Inc. announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as its President. In preparation for Robert Tessarolo's appointment, NeonMind founder Penny White has been appointed Executive Chairman of the Board and stepped down as President of NeonMind. Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., from September 2019 to January 2020.お知らせ • Jan 13NeonMind Biosciences Inc. Appoints C. Laird Birmingham as Board of AdvisorsNeonMind Biosciences Inc. announced that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind's Board of Advisors.お知らせ • Jan 08NeonMind Biosciences Inc. Appoints Trevor Millar as Chief Psychedelic OfficerNeonMind Biosciences Inc. announced that it has appointed Trevor Millar as Chief Psychedelic Officer of the company as of January 6, 2021. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、NeonMind Biosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:NEON - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/2023N/A-100N/A11/30/2022N/A-2-1-1N/A8/31/2022N/A-2-2-2N/A5/31/2022N/A-4-3-3N/A2/28/2022N/A-5-5-5N/A11/30/2021N/A-7-6-6N/A8/31/2021N/A-7-5-5N/A5/31/2021N/A-6-4-4N/A2/28/2021N/A-4-2-2N/A11/30/2020N/A-2-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NEONの予測収益成長が 貯蓄率 ( 1.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NEONの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NEONの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NEONの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NEONの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NEONの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/10 15:31終値2023/03/31 00:00収益2023/02/28年間収益2022/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NeonMind Biosciences Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 15Lancaster Lithium Inc. signed a binding letter agreement to acquire NeonMind Biosciences Inc. (CNSX:NEON) for CAD 0.19 million in a reverse merger transaction.Lancaster Lithium Inc. signed a binding letter agreement to acquire NeonMind Biosciences Inc. (CNSX:NEON) for CAD 0.19 million in a reverse merger transaction on December 14, 2022. At the closing of the Transaction, NeonMind will acquire 100% of the outstanding securities in Lancaster Lithium in exchange for the issuance of post-Consolidation NeonMind shares on a 1:1 basis. Prior to the closing of the Transaction, NeonMind is obligated to complete the consolidation of shares at the ratio of one new share for every thirty existing shares. The completion of the Transaction is subject to the satisfaction of various conditions that are customary for a transaction of this nature, including but not limited to; the completion of the Consolidation; NeonMind and Lancaster Lithium obtaining all required director and shareholder approvals; and the receipt of all requisite regulatory, stock exchange or governmental authorizations and consents, including the authorization and consent of the CSE. Closing of the Transaction to occur no later than March 4, 2022.
お知らせ • Dec 10+ 1 more updateNeonMind Biosciences Inc. Announces CEO ChangesNeonMind Biosciences Inc. announced that Rob Tessarolo, a director on the NeonMind Board of Directors, was appointed Chief Executive Officer on December 7, 2022. Mr. Tessarolo replaces Penny White, who has resigned as Chief Executive Officer as of December 7, 2022, but continues to serve as a director of the Company. Rob joined the Company in January 2021 and is an experienced executive who brings over 25 years of experience in management. The CEO and Board of Directors are currently reviewing new opportunities and are seeking a buyer for the Company's drug development program.
Board Change • Nov 16No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Co-Founder, CEO & Director Penny White is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • May 31+ 1 more updateNeonMind Biosciences Inc. Announces Executive ChangesNeonMind Biosciences Inc. announced that has made changes to its Management, Board of Directors, and Advisory Board to support the Company's strategic plans. Effective May 30, 2022, Rob Tessarolo has been appointed as Chairman of the Board of NeonMind and has resigned from his role as President. Ms. White continues as a member of the Board of Directors. Also on May 30, 2022, Kari Richardson and Jeff B Smith resigned as Directors of the Board of Directors. Kari Richardson has been appointed to serve on the Company's advisory board. Cole Drezdoff and Rob Tessarolo have been appointed to the Company's Board of Directors to fill the vacancies. The Company's Board of Directors now consists of Rob Tessarolo, Penny White, and Cole Drezdoff, and each of them is a member of the Audit Committee, with Rob Tessarolo appointed as Audit Committee Chair. Ms. White continues as a member of the Board of Directors. Robert Tessarolo has 26 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of NeonMind from January 2021 to May 2022. Prior to that, he acted as President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., a psychedelic drug discovery and drug development company now traded on the NEO exchange, from September 2019 to January 2020. Prior, Mr. Tessarolo was President and Chief Executive Officer of Cipher Pharmaceuticals Inc., a diversified specialty pharmaceutical company listed on the Toronto Stock Exchange. Mr. Tessarolo has extensive strategic experience and an impressive operational record of scaling high growth organizations in the pharmaceutical industry through product innovation and M&A. Cipher Pharmaceuticals Inc., which focuses on acquisitions, inlicensing, and selective investments in drug development, under his leadership, was restored to positive EBITDA with the execution of seven business development transactions in less than 18 months. He was the first employee of Watson Pharmaceuticals in Canada. Under his leadership revenue grew from zero to $190 million and he led the Canadian integration of major M&A transactions including Watson integration of Warner Chilcott (~$5 billion global acquisition), Forest Laboratories (~$28 billion global acquisition) and Allergan (~$66 billion global acquisition) in less than 18 months. He has secured tens of millions in financing and hundreds of millions in revenue for companies under his leadership. Cole Drezdoff has been a Director and member of the Audit Committee of Better Plant Sciences Inc. since July 2020. He recently completed four years of fulltime accounting and marketing courses at Toronto Metropolitan University at the Ted Rogers School of Management. Mr. Drezdoff developed experience over the past five years as a consultant in social media, sales, investor relations and business development.
Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Co-Founder & Executive Chairperson Penny White is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 20NeonMind Biosciences Inc Engages Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health ClinicNeonMind Biosciences Inc. announced it has advanced its strategy to enhance access to treatments at its specialty mental health clinics with Impetus Digital in preparation of opening its inaugural clinic located in Mississauga, Ontario. Intravenous ketamine for mood and anxiety disorders (IV-Ket) was recently included in the Canadian guidelines as a recommended treatment. As a testament to the value of IV-Ket treatments, a growing number of prescribers and their patients are seeking access to this treatment with further opportunities to expand the prescriber base through medical education. NeonMind will be working with Impetus Digital's InSite Platform®, a trusted platform for virtual medical education to enhance adoption of IV-Ket treatments. This platform will enable to establish prescriber confidence to include IV-Ket in their treatment toolset and how to refer patients to NeonMind clinics. Impetus Digital has been integral in successful pharmaceutical and healthcare treatment launches in Canada.
お知らせ • Apr 09NeonMind Biosciences Inc. announced that it has received CAD 0.285 million in fundingOn April 8, 2022, NeonMind Biosciences Inc. closed the transaction. The company has received gross proceeds of CAD 285,000 in the transaction. The company also issued 3,743,000 warrants to purchase common shares of the company. The company has paid CAD 14,000 cash commission and granted 133,000 warrants to Echelon Wealth Partners Inc.
お知らせ • Feb 24NeonMind Biosciences Inc. Appoints Dinesh Bhayana as Site Medical Director of Its Inaugural Specialty Mental Health ClinicNeonMind Biosciences Inc. announced the appointment of Dr. Dinesh Bhayana, MD, CCFP (EM), as the Site Medical Director of its recently announced inaugural specialty clinic for interventional psychiatry, located in Mississauga, Ontario. Dr. Bhayana is the Chief Medical Officer of the Centre for Compassionate Care (C3), which offers specialized psychological services including Integrative Ketamine-Enhanced Psychotherapy, served as a Board Member for the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada, and an Emergency and Addiction Medicine physician in several communities within the Greater Toronto Area. NeonMind and Dr. Bhayana will work closely with medical leaders in NeonMind's Specialty Clinics Advisory Board to set up the Company's inaugural NeonMind specialty mental health clinic in Mississauga and leverage their clinical experience to meet regulatory licensing requirements and initiate treatment services this year.
お知らせ • Feb 18NeonMind Biosciences Inc. Announces the Resignation of Amber Allen as Vice President of SalesNeonMind Biosciences Inc. announced the resignation of Amber Allen as Vice President of Sales effective January 17, 2022, which was in connection with the divestiture of the NeonMind consumer division assets.
お知らせ • Nov 24NeonMind Biosciences Inc. Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001NeonMind Biosciences Inc. announced it successfully completed a pre-Investigational New Drug (IND) consultation with the U.S. Food and Drug Administration (FDA), regarding proposed clinical trials for NeonMind's lead obesity drug candidate, NEO-001. The Company expects to initiate a Phase 1/2 clinical study in the first half of 2022. The pre-IND consultation offered feedback for NeonMind to execute on measurable clinical development milestones for its NEO-001 clinical program. The FDA acknowledged the study rationale and potential therapeutic opportunity of NEO-001 for the treatment of obesity, and the justification to advance into human clinical trials. NeonMind will incorporate the FDA's recommendations and does not expect any impact on the timing of the proposed NEO-001 clinical program. NeonMind's proprietary therapy will be the first psychedelic program in humans to target a large population of patients struggling with sustainable weight management. NEO-001, the Company' lead drug candidate targeting obesity, is a high-dose psilocybin treatment coupled with behavioral therapy and lifestyle intervention, which aims to improve the efficacy of chronic weight management in adults. The Company has identified a regulatory strategy, including a target indication and product profile, which it believes will best position NeonMind as it advances its first lead candidate through development.
お知らせ • Sep 14+ 1 more updateBetter Plant Sciences Inc. (CNSX:PLNT) acquired Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON).Better Plant Sciences Inc. (CNSX:PLNT) acquired Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON) on September 10, 2021. The consideration paid by Better Plant to NeonMind Biosciences CAD 0.645 million plus a royalty of 3% of net product sales payable by Better Plant to NeonMind Biosciences for 25 years, payable on cumulative net product sales of over CAD 1 million and payment of CAD 0.645 was made by setting off the balance due of CAD 0.645 on a note owed by NeonMind Biosciences to Better Plant which would have been payable in February 2022. Better Plant Sciences Inc. (CNSX:PLNT) completed the acquisition of Functional Mushroom Assets from NeonMind Biosciences Inc. (CNSX:NEON) on September 10, 2021.
お知らせ • Jul 01Neonmind Biosciences Inc. Launches Its Neonmind Branded Functional Mushroom Coffee Products as Dietary Supplements in the United StatesNeonMind Biosciences Inc. announce that it is launched its NeonMind branded functional mushroom coffee products as dietary supplements in the United States. The initial launch includes two ground coffee SKUs that are available for delivery anywhere within the US. Two instant coffee SKUs are anticipated to be added within a month. Products can be purchased individually and can be ordered as a subscription to receive a 10% discount The website was built to be mobile friendly and focus on a customer- first strategy. Consumers can sign up to NeonMind's newsletter to receive the latest news, product releases and recipe information. Each of the functional mushroom blends and botanicals selected in NeonMind coffees include adaptogens, which means that they work with one's body to help manage physical, mental and emotional stressors. Functional mushroom specifically refers to mushroom varieties that have a health benefit beyond providing nutrition. Functional mushrooms found in NeonMind coffees, such as cordyceps, lion's mane, reishi, and turkey tail; offer long-term physical, neurological and immunological benefits. The initial product launch will feature two varieties of ground coffee. The Protect Blend is a Peruvian Medium Roast French Vanilla Coffee, Turkey Tail, Cordyceps, Moringa extract, and Amla extract. These ingredients have the proven benefit of stress relief, immune support, and cognitive support. The Focus Blend is a Peruvian Dark Roast Coffee with Lion's Mane extract, Reishi extract, Gotu Kola extract, and Brahmi extract. These ingredients are a healthy source of fungal polysaccharides with immuno- modulating properties that help improve memory and cognitive function, increase alertness, support the immune system and fight mental and physical stress. The Company will soon launch its two instant coffee blends in the US as dietary supplements. The NeonMind coffee dietary supplements follow all FDA regulations that focus on Comprehensive GMP (Good Manufacturing Practices) to ensure the identity, purity, quality, strength and composition of dietary supplements. NeonMind only uses certified organic mushroom extracts which go through the decoction process (traditional water boiling) to maximize the bioavailability of the product. NeonMindfollows strict US pharmacopeia guidelines for lead and other chemicals required by Proposition 65 for safe and daily intake. All final production batches are sent to a third party lab for stringent microbial testing in order for the copacker to release the product certificate of analysis which signifies that the product is safe for the consumer market.
お知らせ • Mar 20NeonMind Biosciences Inc., Annual General Meeting, May 27, 2021NeonMind Biosciences Inc., Annual General Meeting, May 27, 2021. Location: Suite 800, 365 Bay Street Toronto Ontario Canada
お知らせ • Mar 04NeonMind Biosciences Inc. Files Four Additional Provisional Patents on Psilocybin Preclinical DataNeonMind Biosciences Inc. announced that it has filed four new provisional patent applications with the United States Patent and Trademark Office to protect initial data obtained during NeonMind's preclinical trial. The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind's proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time. This patent has also been included to support NeonMind's first filed U.S. provisional patent which has a priority date of December 4, 2019, and has been converted to a Patent Cooperation Treaty ("PCT") application. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in 152 countries. NeonMind's patent portfolio has potential rights in 152 countries including the United States. It has filed 10 US provisional patent applications, of which 2 have been converted to PCT applications. The anticipated patent protection expiry of these pending patents is 2041. NeonMind anticipates that its near term activities will support additional applications filed later this year. Compounds now covered by NeonMind's pending patents include: Psilocin, Psilocybin, 4-SH-dimethyltryptamine, 1-methylpsilocin, 4-fluoro-N,N-dimethyltryptamine, O-acetylpsilocin, 4-hydroxy-N-methyl-N-isopropyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, LSD, LSA, DMT. Treatments that are covered by NeonMind's pending patents include: Aiding Weight Loss, Obesity, Compulsive Eating Disorder, Diet Alteration, Reduction of Food Cravings, Decreasing Food Intake, Complications Associated with Obesity. NeonMind owns 100% of all of Its intellectual property except for patents surrounding LSD, LSA and DMT, of which it owns 80%. Translational Life Sciences Inc. a research collaborator, owns the remaining 20%.
お知らせ • Feb 26NeonMind Biosciences Inc. Purchases GMP Grade Synthetic Psilocybin from Psygen Labs Inc. for Phase 2 Human Clinical TrialNeonMind Biosciences Inc. announced that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. for its planned phase 2 human clinical trial expected to begin in Canada later this year. The purchase is made pursuant to a restricted substance supply agreement between Psygen and NeonMind entered into on September 28, 2020. Last year NeonMind received supply under the agreement of non-GMP synthetic psilocybin for its preclinical trial which commenced last November. Now, with promising initial results from its preclinical trial, NeonMind has purchased the GMP grade synthetic psilocybin so it can move forward with an application to Health Canada for a phase 2 human clinical trial. The GMP grade synthetic psilocybin was manufactured through Psygen's collaboration with Applied Pharmaceutical Innovation ("API") and a licensed dealer at the University of Alberta. All the future material will be manufactured at Psygen's soon-to-be completed commercial facility in Calgary. NeonMind may not accept delivery of the psilocybin until it has received authorization from Health Canada. NeonMind filed a provisional patent application in the US, later converted to a patent application, for therapeutic administration of psilocybin alone or in combination with psychotherapy. The patent focuses on psilocybin's potential health benefits for aiding weight loss, diet alterations, reducing food cravings, decreasing food intake, and related health complications. NeonMind plans to study the use of psilocybin alone and in combination with psychotherapy as a treatment for obesity.
お知らせ • Feb 11NeonMind Biosciences Inc. Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight StressNeonMind Biosciences Inc. ("NeonMind"), announced that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD), to obtain product licenses for its products with 100% plant-based extracts, and make their related health claims. The formulas primarily consist of combinations of medicinal mushrooms: Lion's Mane, Reishi, Turkey Tail and Cordyceps. Certain herbs traditionally used in Ayurveda were also included in the formulas. The NeonMind proprietary formulas were created by an expert of Ayurvedic medicine. If the claim applications are deemed acceptable through Health Canada's regulatory review process, then NeonMind will be able to launch natural health products in Canada containing the herbal and fungi formulations described in the NHP applications. Under the natural health product number ("NPN") assigned by Health Canada, NeonMind will be allowed to market these products in different capacities as long as they contain the same makeup and quantities of herbs that are authorized for sale by Health Canada. Health claims submitted as part of the NHP applications by NeonMind include claims that one or more of the formulas can help support memory and cognitive function, support the body's immune response, be used as an adaptogen to help increase energy and resistance to stress (in the case of mental and physical fatigue related to stress), relieve pain and inflammation, and the claim of traditional use in Ayurveda to relieve general debility (especially during convalescence or old age). All natural health products need to obtain a product licence with detailed information about the medicinal ingredients, source, dose, potency, non medicinal ingredients, recommended use, and appropriate risk mitigation statements to be sold in Canada. Once the product is assessed to be safe, effective and of high quality Health Canada issues a product licence an NPN number, allowing it to make health claims. eonMind's consumer products division currently has four mushroom infused coffees that do not contain any psychoactive or restricted substances for sale in Canada through NeonMind's direct-to-consumer ecommerce platform at neonmind.com. NeonMind has plans to launch additional products in Canada as natural health products if Health Canada approves its recent applications. NeonMind's consumer division operates in the rapidly growing functional food market. NeonMind also plans to launch dietary supplements in the United States and is currently developing products and packaging for four products to be manufactured to comply with the United States Food and Drug Administration (FDA) rules. NeonMind plans to roll out these products for sale in the U.S. in spring 2021. In addition to its consumer products division, NeonMind's pharmaceutical division is engaged in the research and development of drugs and treatments for obesity and obesity related diseases using psychedelic compounds. It is currently engaged in a preclinical trial examining its patent pending treatment of obesity through the administration of psilocybin and is currently developing protocols for a phase 2 human clinical trial.
Recent Insider Transactions • Feb 03Co-Founder & Executive Chairperson recently bought CA$76k worth of stockOn the 29th of January, Penny White bought around 282k shares on-market at roughly CA$0.27 per share. In the last 3 months, there was an even bigger purchase from another insider worth CA$425k. This was Penny's only on-market trade for the last 12 months.
お知らせ • Jan 29Neonmind Biosciences Inc. Announces CEO ChangesNeonMind Biosciences Inc. announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as its Chief Executive Officer. Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., from September 2019 to January 2020. Prior, Mr. Tessarolo was President and Chief Executive Officer of Cipher Pharmaceuticals Inc. In preparation for Robert Tessarolo's appointment, NeonMind founder Penny White steps down as President and CEO of NeonMind.
お知らせ • Jan 28NeonMind Biosciences Inc. Appoints Robert Tessarolo as PresidentNeonMind Biosciences Inc. announced the appointment of accomplished pharmaceutical executive Robert Tessarolo as its President. In preparation for Robert Tessarolo's appointment, NeonMind founder Penny White has been appointed Executive Chairman of the Board and stepped down as President of NeonMind. Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently, he held the position of President and Chief Executive Officer of Mind Medicine (Mindmed) Inc., from September 2019 to January 2020.
お知らせ • Jan 13NeonMind Biosciences Inc. Appoints C. Laird Birmingham as Board of AdvisorsNeonMind Biosciences Inc. announced that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind's Board of Advisors.
お知らせ • Jan 08NeonMind Biosciences Inc. Appoints Trevor Millar as Chief Psychedelic OfficerNeonMind Biosciences Inc. announced that it has appointed Trevor Millar as Chief Psychedelic Officer of the company as of January 6, 2021.